tbuckley/cabot-search huggingface dataset:
MB-53hTERT EXPRESSION AND REGULATION IN PEDIATRIC MEDULLOBLASTOMA (MB)
Authors: Ralph Salloum, co-first author, Matthew Sobo, co-first author, Patricia Cobb, Volker Hovestadt, Vijay Ramaswamy, Marc Remke, Lindsey Hoffman, Phillip Dexheimer, Ashley Margol, Charles Stevenson, Shahab Asgharzadeh, Stewart Goldman, Lili Miles, Jie Huang, Katja von Hoff, Stefan Rutkowski, Arzu Onar-Thomas, Uri Tabori, Michael Taylor, Stefan Pfister, Maryam Fouladi, Rachid Drissi
Journal: Neuro-Oncology (2016)
Imipramine response in deluded depressive patients
Authors: F Quitkin, A Rifkin, D F Klein
Journal: American Journal of Psychiatry (1978)

The authors examined how delusions and other psychotic features influenced treatment outcome with imipramine in patients with primary depression. Global improvement scores indicated that delusions or other evidence of psychosis do not contraindicate imipramine treatment. This finding does not support a recent report suggesting that deluded depressive patients should not be treated with imipramine. Possible explanations of the discrepancy between these two studies are discussed.
Checkpoint Antibodies but not T Cell–Recruiting Diabodies Effectively Synergize with TIL-Inducing γ-Irradiation
Authors: Michael Hettich, Jayashree Lahoti, Shruthi Prasad, Gabriele Niedermann
Journal: Cancer Research (2016)

T cell-recruiting bispecific antibodies (bsAb) show promise in hematologic malignancies and are also being evaluated in solid tumors. In this study, we investigated whether T cell-recruiting bsAbs synergize with hypofractionated tumor radiotherapy (hRT) and/or blockade of the programmed death-1 (PD-1) immune checkpoint, both of which can increase tumor-infiltrating lymphocyte (TIL) numbers. Unexpectedly, large melanomas treated with hRT plus bsAb (AC133×CD3) relapsed faster than those treated with hRT alone, accompanied by massive TIL apoptosis. This fast relapse was delayed by the further addition of anti-PD-1. Mechanistic investigations revealed restimulation-induced cell death mediated by BIM and FAS as an additional cause of bsAb-mediated TIL depletion. In contrast, the double combination of hRT and anti-PD-1 strongly increased TIL numbers, and even very large tumors were completely eradicated. Our study reveals the risk that CD3-engaging bsAbs can induce apoptotic TIL depletion followed by rapid tumor regrowth, reminiscent of tolerance induction by CD3 mAb-mediated T-cell depletion, warranting caution in their use for the treatment of solid tumors. Our findings also argue that combining radiotherapy and anti-PD-1 can be quite potent, including against very large tumors. Cancer Res; 76(16); 4673-83. ©2016 AACR.
Long-Term Follow-Up of Children with Surgically Treated Yesicorenal Reflux: Postoperative Incidence of Urinary Tract Infections, Renal Scars and Arterial Hypertension
Authors: R Beetz, H Schulte-Wissermann, J Tröger, H Riedmiller, W Mannhardt, O Schofer, R Hohenfellner
Journal: European Urology (1989)
Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant
Authors: Jennifer Richmond, Alissa Robbins, Kathryn Evans, Dominik Beck, Raushan T. Kurmasheva, Catherine A. Billups, Hernan Carol, Sue Heatley, Rosemary Sutton, Glenn M. Marshall, Deborah White, John Pimanda, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Journal: Cancer Research (2016)

Ph-like acute lymphoblastic leukemia (ALL) is a genetically defined high-risk ALL subtype with a generally poor prognosis. In this study, we evaluated the efficacy of birinapant, a small-molecule mimetic of the apoptotic regulator SMAC, against a diverse set of ALL subtypes. Birinapant exhibited potent and selective cytotoxicity against B-cell precursor ALL (BCP-ALL) cells that were cultured ex vivo or in vivo as patient-derived tumor xenografts (PDX). Cytotoxicity was consistently most acute in Ph-like BCP-ALL. Unbiased gene expression analysis of BCP-ALL PDX specimens identified a 68-gene signature associated with birinapant sensitivity, including an enrichment for genes involved in inflammatory response, hematopoiesis, and cell death pathways. All Ph-like PDXs analyzed clustered within this 68-gene classifier. Mechanistically, birinapant sensitivity was associated with expression of TNF receptor TNFR1 and was abrogated by interfering with the TNFα/TNFR1 interaction. In combination therapy, birinapant enhanced the in vivo efficacy of an induction-type regimen of vincristine, dexamethasone, and L-asparaginase against Ph-like ALL xenografts, offering a preclinical rationale to further evaluate this SMAC mimetic for BCP-ALL treatment. Cancer Res; 76(15); 4579-91. ©2016 AACR.
Aminoglycoside resistance of<i>Pseudomonas aeruginosa</i>in cystic fibrosis results from convergent evolution in the<i>mexZ</i>gene
Authors: Michelle H Prickett, Alan R Hauser, Susanna A McColley, Joanne Cullina, Eileen Potter, Cathy Powers, Manu Jain
Journal: Thorax (2016)

Aminoglycoside (AG) resistance of Pseudomonas aeruginosa in cystic fibrosis (CF) is associated with poorer clinical outcomes and is usually due to overexpression of the efflux pump MexXY. MexXY is regulated by mexZ, one of the most commonly mutated genes in CF P. aeruginosa isolates. Little is known about the evolutionary relationship between AG resistance, MexXY expression and mexZ mutations.To test the hypothesis that AG resistance in P. aeruginosa develops in parallel with higher MexXY expression and mexZ mutations.CF P. aeruginosa isolates were compared for chronically infected (CI) adults, CI children and children with new infection.One P. aeruginosa isolate from each patient was analysed for mexZ mutations, mexY mRNA expression and amikacin resistance.56 patients with CF were enrolled: 21 children with new P. aeruginosa infection, 18 CI children and 17 CI adults. Amikacin resistance and mexY mRNA expression were higher in cohorts with longer P. aeruginosa infection. The prevalence of non-conservative mexZ mutations was 0%, 33% and 65% in children with new infection, CI children and CI adults, respectively. The same trend was seen in the ratio of non-conservative to non-synonymous mexZ mutations. Of isolates with non-conservative mexZ mutations, 59% were amikacin-resistant compared with 18% of isolates with non-synonymous mutations. The doubling rate of amikacin resistance and non-conservative mexZ mutations was approximately 5 years.P. aeruginosa mexZ mutations undergo positive selection resulting in increased mexY mRNA expression and amikacin resistance and likely play a role in bacterial adaption in the CF lung.
Two cases of clinical tumor lysis syndrome following lapatinib in HER2 positive breast cancer
Authors: Komei Nishimura, Mikiya Ishihara, Satoshi Tamaru, Yoshiki Yamashita, Takanori Yamaguchi, Hiroyasu Oda, Yumiko Sugawara, Toshiro Mizuno, Naoyuki Katayama
Journal: Annals of Oncology (2015)
Infusions, age, and drug dosages: learning about large-cell lymphoma.
Authors: J M Connors
Journal: Journal of Clinical Oncology (1988)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1988.6.3.407 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3351558 Infusions, age, and drug dosages: learning about large-cell lymphoma. J M ConnorsxJ M ConnorsSearch for articles by this author https://doi.org/10.1200/JCO.1988.6.3.407 PDF "Infusions, age, and drug dosages: learning about large-cell lymphoma.." Journal of Clinical Oncology, 6(3), pp. 407–408© 1988 by American Society of Clinical Oncology
Synthesis of Ferromagnetic Fe<sub>0.6</sub>Mn<sub>0.4</sub>O Nanoflowers as a New Class of Magnetic Theranostic Platform for In Vivo T<sub>1</sub>‐T<sub>2</sub> Dual‐Mode Magnetic Resonance Imaging and Magnetic Hyperthermia Therapy
Authors: Xiao Li Liu, Cheng Teng Ng, Prashant Chandrasekharan, Hai Tao Yang, Ling Yun Zhao, Erwin Peng, Yun Bo Lv, Wen Xiao, Jie Fang, Jia Bao Yi, Huan Zhang, Kai‐Hsiang Chuang, Boon Huat Bay, Jun Ding, Hai Ming Fan
Journal: Advanced Healthcare Materials (2016)

Uniform wüstite Fe 0.6 Mn 0.4 O nanoflowers have been successfully developed as an innovative theranostic agent with T 1 ‐T 2 dual‐mode magnetic resonance imaging (MRI), for diagnostic applications and therapeutic interventions via magnetic hyperthermia. Unlike their antiferromagnetic bulk counterpart, the obtained Fe 0.6 Mn 0.4 O nanoflowers show unique room‐temperature ferromagnetic behavior, probably due to the presence of an exchange coupling effect. Combined with the flower‐like morphology, ferromagnetic Fe 0.6 Mn 0.4 O nanoflowers are demonstrated to possess dual‐modal MRI sensitivity, with longitudinal relaxivity r 1 and transverse relaxivity r 2 as high as 4.9 and 61.2 m m −1 s −1 [Fe]+[Mn], respectively. Further in vivo MRI carried out on the mouse orthotopic glioma model revealed gliomas are clearly delineated in both T 1 ‐ and T 2 ‐weighted MR images, after administration of the Fe 0.6 Mn 0.4 O nanoflowers. In addition, the Fe 0.6 Mn 0.4 O nanoflowers also exhibit excellent magnetic induction heating effects. Both in vitro and in vivo magnetic hyperthermia experimentation has demonstrated that magnetic hyperthermia by using the innovative Fe 0.6 Mn 0.4 O nanoflowers can induce MCF‐7 breast cancer cell apoptosis and a complete tumor regression without appreciable side effects. The results have demonstrated that the innovative Fe 0.6 Mn 0.4 O nanoflowers can be a new magnetic theranostic platform for in vivo T 1 ‐T 2 dual‐mode MRI and magnetic thermotherapy, thereby achieving a one‐stop diagnosis cum effective therapeutic modality in cancer management.
Endoscopic needle knife fistulotomy technique for ileal pouch-to-pouch fistula
Authors: Vivian Chidi, Bo Shen
Journal: Endoscopy (2015)

A 19-year-old woman with refractory pan-ulcerative colitis, diagnosed in 2004, underwent a total proctocolectomy in 2006, followed by a two-stage ileoanal pull-through procedure. Severe pouchitis led to a two-stage J-pouch reconstruction in 2012. In June 2014, magnetic resonance enterography showed a pre-sacral abscess, which was drained percutaneously.
Dysfunctions in public psychiatric bureaucracies
Authors: L R Marcos
Journal: American Journal of Psychiatry (1988)

The author describes common dysfunctions in public psychiatric organizations according to the model of bureaucracy articulated by Max Weber. Dysfunctions are divided into the categories of goal displacement, outside interference, unclear authority structure and hierarchy, and informal relations in the work place. The author emphasizes the bureaucratic nature of public psychiatry and the need for mental health professionals to understand the dysfunctions of the organizations in which they work, including the impact of these dysfunctions on the provision of quality care.
Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy
Authors: Sung Duk Jo, Sook Hee Ku, You-Yeon Won, Sun Hwa Kim, Ick Chan Kwon
Journal: Theranostics (2016)

Recently, many theranostic nanomaterials have been developed by integrating therapeutic and diagnostic agents in a single regimen.Real-time visualization of nano drug carrier biodistributions, drug release processes and therapeutic responses can provide critical information needed for dynamically optimizing treatment operations in a personalized manner in real time.This review highlights recent progresses in the development of multifunctional nanoparticles possessing both therapeutic and imaging functionalities for cancer therapy.The advantages of using nanoparticle platforms are discussed.Examples demonstrating various combinations of imaging and therapeutic modalities are highlighted.
Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype
Authors: Melissa K McConechy, Anniina Färkkilä, Hugo M Horlings, Aline Talhouk, Leila Unkila-Kallio, Hannah S van Meurs, Winnie Yang, Nirit Rozenberg, Noora Andersson, Katharina Zaby, Saara Bryk, Ralf Bützow, Johannes B G Halfwerk, Gerrit K J Hooijer, Marc J van de Vijver, Marrije R Buist, Gemma G Kenter, Sara Y Brucker, Bernhard Krämer, Annette Staebler, Maaike C G Bleeker, Markku Heikinheimo, Stefan Kommoss, C Blake Gilks, Mikko Anttonen, David G Huntsman
Journal: JNCI Journal of the National Cancer Institute (2016)

The histopathologic features of adult granulosa cell tumors (AGCTs) are relatively nonspecific, resulting in misdiagnosis of other cancers as AGCT, a problem that has not been well characterized. FOXL2 mutation testing was used to stratify 336 AGCTs from three European centers into three categories: 1) FOXL2 mutant molecularly defined AGCT (MD-AGCT) (n = 256 of 336), 2) FOXL2 wild-type AGCT (n = 17 of 336), 3) misdiagnosed other tumor types (n = 63 of 336). All statistical tests were two-sided. The overall and disease-specific survival of the misdiagnosed cases was lower than in the MD-AGCTs (P < .001). The misdiagnosed cases accounted for 71.9% of disease-specific deaths within five years. In the population-based cohort, overall survival of MD-AGCT patients was not different from age-matched, population-based controls. Even though 35.2% of all the MD-AGCT patients in our study experienced a relapse, AGCT is usually an indolent disease. The historical, premolecular data underpinning our clinical understanding of AGCT was likely skewed by inclusion of misdiagnosed cases, and future management strategies should reflect the potential for surgical cure and long survival even after relapse.
Incidence, Predictors, and Outcome of Patients Developing Infective Endocarditis Following Transfemoral Transcatheter Aortic Valve Replacement
Authors: Norman Mangner, Felix Woitek, Stephan Haussig, Florian Schlotter, Georg Stachel, Robert Höllriegel, Johannes Wilde, Anna Lindner, David Holzhey, Sergey Leontyev, Friedrich W. Mohr, Gerhard Schuler, Axel Linke
Journal: Journal of the American College of Cardiology (2016)
P61 Pegylated interferon and ribavarin combination therapy achieves hepatitis E virus clearance in chronic hepatitis E virus/human immunodeficiency virus co-infection
Authors: H Dalton, R Bendall, F Keane, R Neale, R Tedder, S Ijaz
Journal: Gut (2010)

Introduction  Chronic hepatitis E virus (HEV) infection, with rapidly progressive cirrhosis, has recently been documented in immunosuppressed solid organ transplant recipients. In this setting HEV viral clearance can be achieved by either reducing the dose of immunosuppressive agents or by the use of pegylated interferon and/or ribavarin. Chronic HEV infection has also been observed in patients co-infected with human immunodeficiency virus (HIV).1 Acute and chronic HEV is sometimes associated with sensory/motor neuropathy.  Aim  To describe the clinical and laboratory features of HEV/HIV co-infection, and response to antiviral therapy.  Method  A 48-year-old bisexual male was found to be infected with HIV-1 in 2001. In 2003 he was treated for military tuberculosis. Following this he developed a painful, progressive sensory peripheral neuropathy affecting the lower limbs. In 2007 he was noted to have abnormal LFTs. After loss to follow-up, repeat LFTs remained abnormal and a liver biopsy (2009) showed established cirrhosis with active inflammation. Chronic HEV infection was documented with persisting viraemia in serum and stool over a 3 year period (Jan 2007–Jan 2010). HEV was also recovered from his cerebrospinal fluid. He remained antiretroviral naive until January 2007, when he commenced on tenofovir/emtricitabine and lopinavir/ritonavir. Although transiently switched to efavirenz he settled on his current regimen of abacavir/lamivudine and lopinavir/ritonavir in June 2007. His HIV viral load became undetectable but his CD4 count remained low (100–170 /mm 3 ).  Results  In July 2009 he was treated with Pegasys 135 microg/week. His LFTs normalised and his HEV viral load declined. At 6 months he achieved HEV clearance from his serum, but HEV was still detectable in stool. Ribavarin 1 g/day was added in for a further 3 months. HEV viral clearance was achieved from serum and stool. During treatment, neurological symptoms improved and, by the time viral clearance was achieved, they were abolished. He remains HEV PCR negative 3 months after completion of therapy.  Conclusion  Chronic HEV infection can occur in the context of HIV and can be associated with neurological symptoms. HEV viral clearance can be achieved by combination therapy with Pegasys/ribavarin, with normalisation of LFT9s and resolution of neurological symptoms. The mechanism of neurological damage in HEV infection is uncertain.
PNR-05PRIMITIVE MYXOID MESENCHYMAL TUMOUR OF INFANCY – A CASE OF EARLY CHEMOTHERAPY-RESPONSIVENESS AND REVIEW OF THE LITERATURE
Authors: Charlotte Burns, Juliet Clayton, Jessica Ng, Jordan Hansford
Journal: Neuro-Oncology (2016)

PNR-05. PRIMITIVE MYXOID MESENCHYMAL TUMOUR OF INFANCY – A CASE OF EARLY CHEMOTHERAPYRESPONSIVENESS AND REVIEW OF THE LITERATURE Charlotte Burns1, Juliet Clayton2, Jessica Ng3, and Jordan Hansford1; The Children’s Cancer Centre, The Royal Children’s Hospital, Melbourne, Australia; The Department of Neurosurgery, The Royal Children’s Hospital, Melbourne, Australia; The Department of Anatomical Pathology, The Royal Children’s Hospital, Melbourne, Australia Primitive myxoid mesenchymal tumour of infancy (PMMTI) is a newly described mesenchymal tumour occurring within the first year and with a predilection for deep soft tissue around the spinal cord. Histologically characterised by proliferation of primitive immature mesenchymal cells and distinctive myxoid background, it is rare with less than twenty reported cases. Complete surgical resection provides optimal disease control, as tumours are locally aggressive and recur early. Rarely, metastases or transformation to higher-grade lesions has been observed. Systemic therapy has added little value to date. We presentaneonatewith PMMTI andanearly response tochemotherapy.A term neonate admitted at twenty-one days old with bronchiolitis was noted to have progressive lower limb weakness, urinary retention and reduced anal tone. MRI spine showed an enhancing soft tissue mass within the spinal canal extending fromL1-L5. Completemacroscopic surgical resectionwasperformed. Histologywas consistentwith PMMTI. Within threemonths, progressiveneurological deficits recurred. Repeat MRI revealed unresectable, extensive local recurrence with intraand extra-spinal components and biopsy confirmed identical histology. With limited therapeutic options available, chemotherapy was initiated (ifosfamide, carboplatin and etoposide, followed by vincristine, actinomycin, cyclophosphamide and doxorubicin). Therewasmarked clinical improvement after one cycle and 35% tumour volume reduction on MRI after two. Chemotherapy-responsiveness to this extent has not been documented to our knowledge. We present a case of PMMTI presenting typically, but with an early response to aggressive sarcoma-based chemotherapy. This treatment could be considered for unresectable PMMTI, an increasingly recognised entity, in the future. Neuro-Oncology 18:iii7–iii15, 2016. doi:10.1093/neuonc/now067.5 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Hypervitaminosis A—Hyperostosis Corticalis (Caffey): Differential Diagnostic Considerations
Authors: O MUNE, S NORREGAARD
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MB-67DUAL TARGETING OF PI3K AND mTOR SIGNALING IN MEDULLOBLASTOMA
Authors: Jessica Clymer, Frank Eckerdt, Jonathan Bell, Rishi Lulla, Stewart Goldman, Leonidas Platanias
Journal: Neuro-Oncology (2016)

MB-67. DUAL TARGETING OF PI3K AND mTOR SIGNALING IN MEDULLOBLASTOMA Jessica Clymer1,2, Frank Eckerdt2, Jonathan Bell2, Rishi Lulla1,2, Stewart Goldman1,2, and Leonidas Platanias2,3; Division of Hematology/ Oncology/Stem Cell Transplantation, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital, Chicago, IL, USA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA BACKGROUND: Aberrant activation of the PI3K pathway has been shown to play a role in medulloblastoma cell proliferation, while mTOR activation contributes to therapy resistance. Here we sought to evaluate the effects of combined targeting of the PI3K and mTOR pathways in medulloblastoma. METHODS: Medulloblastoma cell lines Daoy and D556 were grown in 2-D cultures to investigate the effects of pharmacologic inhibition of PI3K and mTORon kinase signaling, medulloblastomacell proliferation, colony formation, and apoptosis. After knockdown of p110 isoforms, cells were also grown under stem cell conditions as 3-D neurospheres and subjected to extreme limiting dilution analysis (ELDA) for assessment of stem-like cancer cell growth. RESULTS: Of all class I PI3K isoforms (p110a, p110b, p110d, and p110g), only p110a was essential for medulloblastoma cell proliferation, colony formation and neurosphere growth. Accordingly, pharmacologic targeting of the p110a isoform of PI3K with BYL-719 synergizedwith the mTOR inhibitor OSI-027, as it resulted in inhibition of effector pathways, blocked cell proliferation and colony formation, and increased malignant cell death by apoptosis. Finally,BYL-719and OSI-027 greatly impairedgrowthof stem-likecancer cells as 3-D neurospheres. CONCLUSIONS: The p110a isoform of PI3K exerts crucial roles in medulloblastoma. Inhibition of p110a and mTOR exerts potent antineoplastic effects on medulloblastoma cells and also blocks neurosphere growth. Dual inhibition of p110a and mTOR might be promising for targeting both malignant medulloblastoma cells and the therapy-resistant cancer stem cell population. Neuro-Oncology 18:iii97–iii122, 2016. doi:10.1093/neuonc/now076.63 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.